Arava Articles

New Zealand's PHARMAC agrees pricing deal with Sanofi for Arava

4 September 2012

Batch of approvals and positive opinions from EU’s CHMP

26 October 2009

Combining medications often best strategy to battle rheumatoid arthritis; study

3 December 2007

Calls for postmarket trials resisted as GAO slams USA

1 May 2006

Aventis welcomes FDA's Arava decision

12 April 2004

Tokyo pharma stocks - week to March 22

29 March 2004

Alexion's eculizumab shows mixed results for RA but promise for PNH

9 February 2004

Aventis confirms five deaths in Japan associated with Arava

2 February 2004

Aventis' Arava now available in Japan

22 September 2003

FDA OK's expanded use for Arava

23 June 2003

Aventis' Arava licensed in Japan for RA

28 April 2003

FDA panel supports safety of biologicals in rheumatoid arthritis

10 March 2003

Funding and approving new drugs in Israel's NHI basket

18 February 2002

Aventis growth driven by strong US pharmaceutical sales

6 November 2001

US pharmaceutical sales driving growth at Aventis as 2nd-qtr profits rise

2 August 2001

CORRECTION: Aventis' Arava

24 May 2001

Aventis reports liver problems with Arava

10 May 2001

US pharmaceutical sales driving growth at Aventis as profits leap 82%

10 May 2001

Massive hike in net income for Aventis in 2000 as focus is firmly placed on

2 March 2001

Aventis' Arava "enhances treatment"

30 October 2000

Aventis' Arava shows functional benefits

26 June 2000

BASF Pharma sees D2E7 filing next year; potential against Enbrel and

23 June 2000

Arava shows early benefit in RA

22 June 2000

First disclosure of Aventis' early-stage R&D pipeline

23 May 2000

Aventis net income climbs 63% in 1st qtr

23 May 2000

Two-year data support Arava activity in RA

15 November 1999

HMR boosting profits at Hoechst

8 November 1999

Europe approves HMR's Arava

9 September 1999

HMR helps soften blow as Hoechst profits slide

5 August 1999

Euro pharma firms spell out plans for future growth to US investors

17 June 1999

NovoRapid, Arava backed by CPMP

27 May 1999

Germany's major drugmakers post disappointing sales and earnings for 1st qtr

4 May 1999

HMR has 10 priority projects in development

22 April 1999

US FDA makes progress, says their own product review record for 1998

29 January 1999

Quality, not quantity, sums up New Chemical Entity launches in 1998

7 January 1999

Aventis Pipeline Rich In Near-Term Prospects

10 December 1998

Hoechst & Rhone-Poulenc Merge To Create Aventis

1 December 1998

Centocor Shares Fall As Remicade Warning Goes Out

23 November 1998

Hoechst/Rhone-Poulenc Merger Looks More Likely

17 November 1998

Enbrel Recommended For Approval By US Panel

21 September 1998

First Launch Of HMR's Arava In USA

14 September 1998

Hoechst Sales Down 18% But HMR Pipeline Strong

19 August 1998

HMR's Arava Moves Closer To US Approval

12 August 1998

US Advisory Panel Meetings

22 July 1998

Hoechst Receives Boost From Analysts, Thanks To HMR

2 July 1998

Positive Presentations At Goldman Sachs Conf

15 June 1998

HMR Gets Priority Review For RA Drug

14 May 1998

Hoechst Confirms Life Science Focus

5 May 1998

Bad Times Soon Over, Says Hoechst Marion Roussel

12 March 1998

Anzemet Launched For PONV In USA

26 February 1998

Biotech Promise For Rheumatoid Arthritis

26 February 1998

Mycophenolate Approval in Europe Imminent, Says Roche

19 February 1996

Phase III Leflunomide Trials To Complete By Year-End

26 June 1995

Hoechst Streamlines R&D: Update On Early Pipeline

10 October 1994

Hoechst's Propentofylline Set For Spring '95 Filing

3 October 1994

KYORIN OBTAINS LICENSE

6 June 1994

HOECHST TO LICENSE OUT LEFLUNOMIDE

23 May 1994

LIGHT AT THE END OF THE TUNNEL FOR HOECHST?

28 March 1994

HOECHST PHARMA "LEANER AND MORE FLEXIBLE"

1 November 1993

SYNTEX "A COMPANY ON THE MOVE"

20 January 1992

HOECHST RESEARCH: A "TRI-REGIONAL" FOCUS

20 January 1992

Showing 1-61 of 61 articles

Go to beginningPrevious
  • 1
NextGo to end